Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;8(24):1698.
doi: 10.21037/atm-2020-117.

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial

Meir Schechter  1   2 , Gil Leibowitz  1   2 , Ofri Mosenzon  1   2
Affiliations
Editorial

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial

Meir Schechter et al. Ann Transl Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-2020-117). OM reports grants, personal fees and other from Novo Nordisk, grants, personal fees and other from AstraZeneca, personal fees and other from Eli Lilly, personal fees and other from Sanofi, personal fees and other from Merck Sharp & Dohme, personal fees and other from Boehringer Ingelheim, other from BOL Pharma, outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. IDF Diabetes Atlas 9th edition 2019 [Internet]. [cited 2020 Apr 1]. Available online: https://www.diabetesatlas.org/en/
    1. Chronic Kidney Disease Prognosis Consortium , Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81. 10.1016/S0140-6736(10)60674-5 - DOI - PMC - PubMed
    1. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 2016;316:602-10. 10.1001/jama.2016.10924 - DOI - PMC - PubMed
    1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. 10.1056/NEJMoa011303 - DOI - PubMed
    1. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34. 10.1056/NEJMoa1515920 - DOI - PubMed